Biomica
Rehovot, Israel· Est.
Biomica develops microbiome‑engineered cancer therapeutics, with its lead candidate BMC128 having cleared Phase 1.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Biomica develops microbiome‑engineered cancer therapeutics, with its lead candidate BMC128 having cleared Phase 1.
Oncology
Technology Platform
Computationally designed live bacterial strains that modulate the gut microbiome to enhance anti‑tumor immunity.
Opportunities
Expanding the microbiome platform to multiple oncology indications and leveraging partnerships for accelerated development and commercialization.
Risk Factors
Regulatory uncertainty for live‑biotherapeutics, scientific challenges in demonstrating consistent efficacy, and intense competition in the microbiome space.
Competitive Landscape
Competes with Seres, Finch, and Synlogic; differentiation lies in Evogene’s AI‑driven strain design and a focused oncology pipeline.